Summary

The Middle East and Africa alpha and beta emitters based radiopharmaceuticals market is expected to reach USD 63.69 million by 2032 from USD 30.85 million in 2024, growing with a substantial CAGR of 9.5% in the forecast period of 2025 to 2032.

Market Segmentation:
Middle East and Africa Alpha and Beta Emitters Based Radiopharmaceuticals Market, By Isotope (Beta Emitters and Alpha Emitters), Sources (Reactor-Produced Isotopes, Generator-Produced Isotopes, and Others), Therapeutic Application (Oncology and Others), Vector Type (Small Molecule Ligands, Peptides, Monoclonal Antibodies, and Others), End User (Hospitals, Radiopharmacies, and Research Institutes), Country (South Africa, Egypt, Saudi Arabia, U.A.E., Kuwait, Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2032
Overview of Middle East and Africa Alpha and Beta Emitters Based Radiopharmaceuticals Market Dynamics:
Drivers
• Increased efficacy of targeted alpha and beta therapies
• Growing adoption of theranostics in personalized medicine
• Rising clinical demand for alpha-based radiotherapies
Restraints
• Supply chain and scalability challenges from short isotope half-lives
• Stringent regulatory landscape limiting market flexibility
Opportunities
• Surge in R&D activity expanding radiopharmaceutical applications
• Expansion of Lu-177-PSMA therapy in prostate cancer treatment
Market Players:
The key players operating in the Middle East and Africa alpha and beta emitters based radiopharmaceuticals market are:
• Novartis AG
• Eckert & Ziegler
• Actinium Pharmaceuticals, Inc.
• Alpha Tau Medical Ltd.
• Bayer AG
• Isotopia
• Lilly

ページTOPに戻る

Table of Contents

TABLE OF CONTENTS
1 INTRODUCTION 35
1.1 OBJECTIVES OF THE STUDY 35
1.2 MARKET DEFINITION 35
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 35
1.4 MARKETS COVERED 37
2 MARKET SEGMENTATION 40
2.1 MARKETS COVERED 40
2.2 GEOGRAPHICAL SCOPE 41
2.3 YEARS CONSIDERED FOR THE STUDY 42
2.4 CURRENCY AND PRICING 42
2.5 DBMR TRIPOD DATA VALIDATION MODEL 43
2.6 MULTIVARIATE MODELLING 46
2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 47
2.8 DBMR MARKET POSITION GRID 48
2.9 VENDOR SHARE ANALYSIS 49
2.10 END USER MARKET COVERAGE GRID 50
2.11 SECONDARY SOURCES 51
2.12 ASSUMPTIONS 51
3 EXECUTIVE SUMMARY 52
4 PREMIUM INSIGHT 58
4.1 PORTER’S FIVE FORCES 59
4.2 PESTEL ANALYSIS 60
4.3 PIPELINE 61
4.4 SUPPLY CHAIN ECOSYSTEM 66
4.4.1 PROMINENT COMPANIES 66
4.4.2 SMALL & MEDIUM SIZE COMPANIES 66
4.4.3 END USERS 66
4.5 INDUSTRY INSIGHTS 67
4.5.1 MICRO AND MACRO ECONOMIC FACTORS 67
4.5.2 KEY PRICING STRATEGIES 68
4.6 MARKETED DRUG ANALYSIS 69
4.6.1 DRUG 69
4.6.1.1 BRAND NAME 69
4.6.1.2 GENERIC NAME 69
4.6.2 THERAPEUTIC INDICATION 69
4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG 69
4.6.4 DRUG PRIMARY INDICATION 69
4.6.5 MARKET STATUS 69
4.6.6 MEDICATION TYPE 70
4.6.7 DRUG DOSAGE FORM 70
4.6.8 DOSAGES AVAILABILITY 70
4.6.9 PACKAGING TYPE 70
4.6.10 DRUG ROUTE OF ADMINISTRATION 70
4.6.11 DOSING FREQUENCY 70
4.6.12 DRUG INSIGHT 70
4.6.13 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES 71
4.6.13.1 FORECAST MARKET OUTLOOK 71
4.6.13.2 CROSS COMPETITION 71
4.6.13.3 THERAPEUTIC PORTFOLIO 71
4.6.13.4 CURRENT DEVELOPMENT SCENARIO 71
4.7 HEALTHCARE TARIFFS IMPACT ANALYSIS 72
4.7.1 OVERVIEW 72
4.7.2 TARIFF STRUCTURES 72
4.7.2.1 MIDDLE EAST AND AFRICA VS. REGIONAL TARIFF STRUCTURES 72
4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS 72
4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES 72
4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS 72
4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION 73
4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS 73
4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS 73
4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS 73
4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS 73
4.8 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS 73
4.8.1.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES 73
4.8.1.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE 73
4.8.1.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM 74
4.8.2 TRADE AGREEMENTS AND HEALTHCARE TARIFFS 74
4.8.2.1 WTO REGULATIONS ON HEALTHCARE TARIFFS 74
4.8.2.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN 74
4.8.2.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS 74
4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY 74
4.8.4 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR 74
4.9 EPIDEMIOLOGY OVERVIEW 75
4.9.1 INCIDENCE OF ALL CANCERS BY GENDER 75
4.9.2 TREATMENT RATE 76
4.9.3 MORTALITY RATE 76
4.9.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 77
4.9.5 PATIENT TREATMENT SUCCESS RATES 77
5 REGULATORY FRAMEWORK 79
5.1 REGULATORY FRAMEWORK OVERVIEW FOR THE MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET 85
5.1.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL 85
5.1.2 REGULATORY APPROVAL PATHWAYS 85
5.1.3 LICENSING AND REGISTRATION 86
5.1.4 POST-MARKETING SURVEILLANCE 86
5.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 86
6 MARKET OVERVIEW 87
6.1 DRIVERS 89
6.1.1 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES 89
6.1.2 GROWING ADOPTION OF THERANOSTICS IN PERSONALIZED MEDICINE 89
6.1.3 RISING CLINICAL DEMAND FOR ALPHA-BASED RADIOTHERAPIES 90
6.1.4 RISING CHRONIC DISEASE BURDEN DRIVING RADIOPHARMACEUTICAL DEMAND 91
6.2 RESTRAINTS 92
6.2.1 SUPPLY CHAIN AND SCALABILITY CHALLENGES FROM SHORT ISOTOPE HALF-LIVES 92
6.2.2 STRINGENT REGULATORY LANDSCAPE LIMITING MARKET FLEXIBILITY 92
6.2.3 SAFETY AND EXPOSURE RISKS IN RADIOPHARMACEUTICAL USE 93
6.3 OPPORTUNITIES 94
6.3.1 SURGE IN R&D ACTIVITY EXPANDING RADIOPHARMACEUTICAL APPLICATIONS 94
6.3.2 EXPANSION OF LU-177-PSMA THERAPY IN PROSTATE CANCER TREATMENT 95
6.3.3 STRATEGIC COLLABORATIONS DRIVING RADIOPHARMACEUTICAL INNOVATION 95
6.4 CHALLENGES 96
6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS 96
6.4.2 SHORTAGE OF SKILLED WORKFORCE IN NUCLEAR MEDICINE AND RADIOCHEMISTRY 97
7 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 99
7.1 OVERVIEW 100
7.2 BETA EMITTERS 103
7.2.1 LUTETIUM-177 103
7.2.2 TERBIUM-161 103
7.3 ALPHA EMITTERS 104
7.3.1 ACTINIUM-225 104
7.3.2 LEAD -212 104
8 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES 105
8.1 OVERVIEW 106
8.2 REACTOR-PRODUCED ISOTOPES 109
8.3 GENERATOR-PRODUCED ISOTOPES 109
8.4 OTHERS 110
9 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION 111
9.1 OVERVIEW 112
9.2 ONCOLOGY 115
9.2.1 PROSTATE CANCER 116
9.2.2 NEUROENDOCRINE TUMORS 116
9.2.3 LIVER CANCER 116
9.2.4 BRAIN TUMORS 116
9.2.5 BREAST CANCER 116
9.2.6 LEUKEMIA 116
9.3 OTHERS 116
10 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE 117
10.1 OVERVIEW 118
10.2 SMALL MOLECULE LIGANDS 121
10.3 PEPTIDES 121
10.4 MONOCLONAL ANTIBODIES 122
10.5 OTHERS 122
11 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER 123
11.1 OVERVIEW 124
11.2 HOSPITALS 127
11.2.1 ONCOLOGY CENTERS 127
11.2.2 NUCLEAR MEDICINE DEPARTMENTS 127
11.3 RADIOPHARMACIES 128
11.4 RESEARCH INSTITUTES 128
12 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION 129
12.1 MIDDLE EAST AND AFRICA 131
12.1.1 SOUTH AFRICA 135
12.1.2 EGYPT 138
12.1.3 SAUDI ARABIA 141
12.1.4 U.A.E. 144
12.1.5 KUWAIT 147
12.1.6 ISRAEL 150
12.1.7 REST OF MIDDLE EAST AND AFRICA 153
13 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE 154
13.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 154
14 SWOT ANALYSIS 155
15 COMPANY PROFILES 156
15.1 NOVARTIS AG 156
15.1.1 COMPANY SNAPSHOT 156
15.1.2 REVENUE ANALYSIS 157
15.1.3 COMPANY SHARE ANALYSIS 157
15.1.4 PRODUCT PORTFOLIO 158
15.1.5 RECENT DEVELOPMENTS 158
15.2 ECKERT & ZIEGLER 159
15.2.1 COMPANY SNAPSHOT 159
15.2.2 REVENUE ANALYSIS 159
15.2.3 COMPANY SHARE ANALYSIS 160
15.2.4 PRODUCT PORTFOLIO 160
15.2.5 RECENT DEVELOPMENTS 161
15.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE 162
15.3.1 COMPANY SNAPSHOT 162
15.3.2 COMPANY SHARE ANALYSIS 162
15.3.3 PRODUCT PORTFOLIO 163
15.3.4 RECENT DEVELOPMENT 163
15.4 SHINE TECHNOLOGIES, LLC 164
15.4.1 COMPANY SNAPSHOT 164
15.4.2 COMPANY SHARE ANALYSIS 164
15.4.3 PRODUCT PORTFOLIO 165
15.4.4 RECENT DEVELOPMENT 165
15.5 ACTINIUM PHARMACEUTICALS, INC. 166
15.5.1 COMPANY SNAPSHOT 166
15.5.2 PIPELINE PRODUCT PORTFOLIO 166
15.5.3 RECENT DEVELOPMENTS 167
15.6 ALPHA TAU MEDICAL LTD. 168
15.6.1 COMPANY SNAPSHOT 168
15.6.2 PIPELINE PRODUCT PORTFOLIO 168
15.6.3 RECENT DEVELOPMENT 168
15.7 ARICEUM THERAPEUTICS 169
15.7.1 COMPANY SNAPSHOT 169
15.7.2 PIPELINE PRODUCT PORTFOLIO 169
15.7.3 RECENT DEVELOPMENT 169
15.8 BAYER AG 170
15.8.1 COMPANY SNAPSHOT 170
15.8.2 REVENUE ANALYSIS 170
15.8.3 PIPELINE PRODUCT PORTFOLIO 171
15.8.4 RECENT DEVELOPMENT 171
15.9 CURIUM 172
15.9.1 COMPANY SNAPSHOT 172
15.9.2 PIPELINE PRODUCT PORTFOLIO 172
15.9.3 RECENT DEVELOPMENT 172
15.10 IONETIX CORPORATION 173
15.10.1 COMPANY SNAPSHOT 173
15.10.2 PIPELINE PRODUCT PORTFOLIO 173
15.10.3 RECENT DEVELOPMENT 173
15.11 ISOTOPIA 174
15.11.1 COMPANY SNAPSHOT 174
15.11.2 PIPELINE PRODUCT PORTFOLIO 174
15.11.3 RECENT DEVELOPMENT 174
15.12 LANTHEUS 175
15.12.1 COMPANY SNAPSHOT 175
15.12.2 REVENUE ANALYSIS 175
15.12.3 PIPELINE PRODUCT PORTFOLIO 176
15.12.4 RECENT DEVELOPMENT 177
15.13 LILLY 178
15.13.1 COMPANY SNAPSHOT 178
15.13.2 REVENUE ANALYSIS 178
15.13.3 PIPELINE PRODUCT PORTFOLIO 179
15.14 NIOWAVE 180
15.14.1 COMPANY SNAPSHOT 180
15.14.2 PIPELINE PRODUCT PORTFOLIO 180
15.14.3 RECENT DEVELOPMENT 180
15.15 NMR 181
15.15.1 COMPANY SNAPSHOT 181
15.15.2 PIPELINE PRODUCT PORTFOLIO 181
15.15.3 RECENT DEVELOPMENT 181
15.16 ONCOINVENT 182
15.16.1 COMPANY SNAPSHOT 182
15.16.2 PIPELINE PRODUCT PORTFOLIO 182
15.16.3 RECENT DEVELOPMENT 182
15.17 ORANO GROUP 183
15.17.1 COMPANY SNAPSHOT 183
15.17.2 REVENUE ANALYSIS 183
15.17.3 PIPELINE PRODUCT PORTFOLIO 184
15.17.4 RECENT DEVELOPMENT 185
15.18 RADIOPHARM THERANOSTICS LIMITED 186
15.18.1 COMPANY SNAPSHOT 186
15.18.2 PIPELINE PRODUCT PORTFOLIO 186
15.18.3 RECENT DEVELOPMENT 187
15.19 TELIX PHARMACEUTICALS LIMITED 188
15.19.1 COMPANY SNAPSHOT 188
15.19.2 REVENUE ANALYSIS 188
15.19.3 PIPELINE PRODUCT PORTFOLIO 189
15.19.4 RECENT DEVELOPMENT 190
15.20 TERTHERA 191
15.20.1 COMPANY SNAPSHOT 191
15.20.2 PIPELINE PRODUCT PORTFOLIO 191
15.20.3 RECENT DEVELOPMENT 191
15.20.4 RECENT DEVELOPMENT 191
16 QUESTIONNAIRE 192
17 RELATED REPORTS 195